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ABSTRACT
Much interest and controversy abounds regarding the benefits and
perils associated with the importation of pharmaceuticals. The Inter-
net has provided an uncertain vehicle for such importation especially
as it pertains to two key areas: product authentication and product in-
tegrity. As a result, questions exist as to whether other U.S. entities
may provide a more legitimate and safer alternative to the Internet for
supplying imported prescription pharmaceuticals into the United
States. One such avenue may be the involvement of U.S. pharmaceu-
tical wholesale distributors in the importation process. The pros and
cons of that concept are addressed herein. This essay examines vari-
ous facets of the U.S. pharmaceutical supply chain with a focus upon
legal and regulatory requirements currently in place. In addition, chal-
lenges facing the U.S. pharmaceutical supply chain, such as counter-
feit drugs, are discussed, as well as what is being done to address
those issues in terms of operational and technological approaches.
Lastly, domestic and international legal and regulatory implications
for drug importation by non-manufacturers, as well as importation's
potential impact on the integrity of the U.S. pharmaceutical supply
chain, are assessed. The U.S. pharmaceutical supply chain currently
provides for a closed system wherein safeguards have been estab-
lished to help ensure product integrity. While issues have arisen in the
past, the U.S. pharmaceutical wholesale distribution industry has
taken significant steps in strengthening its systems to help prevent
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counterfeit drugs from entering the U.S. pharmaceutical supply chain.
In addition, while emerging technologies such as Radio Frequency
Identification (RFID) provide promise, significant work is still needed
to ensure effective implementation and consistent results. As such,
given today's environment, the infusion of imported drugs into the
U.S. pharmaceutical supply chain from foreign non-manufacturing
sources may work to substantially undermine the integrity of the U.S.
pharmaceutical supply chain.
INTRODUCTION'
There has been much discussion about the importation of foreign
pharmaceuticals into the United States. Through the Internet, a vari-
ety of pharmacies across the world have emerged to service the de-
mand by U.S. citizens for less expensive drugs. In addition, various
initiatives through Congress have begun, but to date, have not been
implemented to legally provide for the importation of pharmaceuticals
into this country.2 Some of those initiatives have suggested a potential
role that U.S. pharmaceutical wholesale distributors may play in the
importation of prescription pharmaceuticals into the United States.
While the concept has merit, the challenges that exist are significant.
There are two key areas that any approach to importation must
address. The first is product authentication. When U.S. citizens order
their medication, they must be assured that they receive the prescrip-
tion drug in the exact specification ordered by their physician. How-
ever, prescription products are produced differently for various mar-
kets, based on differing standards. In addition to legal differences in
same-brand name pharmaceuticals, it is clear that counterfeiting is a
much more pervasive criminal activity outside the United States. As
such, there is a need to protect against the effects of this insidious
practice. The second key area in approaching importation is to ad-
dress product integrity. There should never be a question about the
strength or safety of any medication supplied to patients. Hence, a
1. Much of the information referred to in this essay is a result of first-hand knowledge
on the part of the author; accordingly, secondary sources have not been referenced for that
information.
2. See 21 U.S.C. § 384(b)(1) (2005). Section 384(b)(1) permits the Secretary of the
U.S. Department of Health and Human Services to promulgate regulations to permit pharma-
cists and wholesalers to import prescription pharmaceuticals into the United States, provided
that safeguards are in place to ensure that such imported items are safe and effective for their
intended use and that the items are in accord with other requirements set forth under the Fed-
eral Food, Drug, and Cosmetic Act. To date, the Secretary has yet to establish a system that
can ensure the safety of such imported product.
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system cannot be developed that does not properly address the multi-
tude of factors that cause degradation of pharmaceuticals.
This essay intends to provide an overview of some of the issues
that currently impact pharmaceutical wholesale distributors, while
evaluating those issues against the backdrop of importation.
DISCUSSION
The U.S. Phannaceutical Wholesaling Industry
The pharmaceutical wholesaling industry has historically been
one that very few people outside of the health care sector even knew
existed. The general public is aware of health care providers (e.g.,
physicians, hospitals, pharmacies, and clinics), in addition to the
manufacturers of pharmaceuticals such as Pfizer (Viagra® and Lipi-
tor®), GlaxoSmithKline (Paxil®), and Abbott (Synthroid®). However,
very little recognition or appreciation was given to how exactly the
drug products make their way from the manufacturer to the thousands
of health care providers across the country. This, in essence, is the
role of the U.S. pharmaceutical wholesale distributor. Without the ef-
forts of the drug wholesale distributor, pharmaceuticals would not be
received on almost a daily basis by the millions of patients that depend
upon them.
The pharmaceutical wholesale distribution industry is comprised
of a number of distributors. Cardinal Health is one of those pharma-
ceutical distributors. Generally, over 90% of the wholesale distribu-
tion industry is serviced by three national wholesale distributors.
These distributors, commonly referred to as the "Big Three," are Car-
dinal Health, AmerisourceBergen, and McKesson. Some other statis-
tics of note are as follows. The trade association to which the Big
Three belong, the Healthcare Distribution Management Association
(HMDA), has approximately forty-six distributor members operating
214 distribution centers in the United States. The average HDMA dis-
tribution center stocks approximately 22,400 items, of which 50% are
prescription pharmaceuticals. In the case of Cardinal Health, the
numbers are bit more daunting. Currently, Cardinal Health keeps over
75,000 different products in its inventory (which averages approxi-
mately 35,000 to 40,000 SKUs per facility). In addition, Cardinal
Health picks and delivers more than two million items per day for
35,000 U.S. customers from their twenty-four pharmaceutical distribu-
tion centers. Cardinal also makes over 25,000 deliveries per day
across the country while servicing approximately 30% of the nation's
2005]
3
Giacalone,: Drug Wholesaling and Importation: Challenges and Opportunities
Published by CWSL Scholarly Commons, 2005
68 CALIFORNIA WESTERN INTERNATIONAL LAW JOURNAL [Vol. 36
needs.
Wholesale distributors are licensed and regulated by a number of
governmental agencies. On a federal level, the U.S. Drug Enforce-
ment Administration (DEA) licenses and inspects pharmaceutical dis-
tributors that handle and distribute controlled substances (e.g., narcot-
ics and other potential drugs of abuse). While not directly licensed by
the U.S. Food and Drug Administration (FDA), there are federal laws
and standards that apply to the industry and allow for the FDA to in-
spect and take action against distributors who fail to act in accordance
with legal mandates.3 Other agencies such as the U.S. Environmental
Protection Agency (EPA) also dictate how distribution centers are run,
and the U.S. Department of Transportation (DOT) impacts how deliv-
eries of pharmaceuticals are made. In addition, on a state level, there
are a number of entities that also license and regulate distributors. In
many cases, the state boards of pharmacy license and regulate dis-
tributors that reside in or provide products into their respective state
from non-resident facilities. However, some states assign this author-
ity to state departments of health or, in one case, to a board of whole-
salers.4 Furthermore, some states also have their own state versions of
the DEA, referred to as state controlled substance agencies, while still
others may have their own versions of the FDA that may also provide
another layer of oversight and regulation of pharmaceutical wholesale
distributors. Hence, as is apparent, a regulatory process to oversee
pharmaceutical wholesale distributors is in place. However, until re-
cently the diligence on the part of regulators to enforce established le-
gal requirements has, at times, varied.
The way the drug distribution process generally works is as one
would expect. Pharmaceutical products originate at the manufacturer
and then are shipped directly to the pharmaceutical wholesale distribu-
tor. At that point, the pharmaceutical wholesale distributor receives
and stores the product in their climate-controlled warehouses pursuant
to the manufacturer's requirements or regulatory dictates (e.g., some
products must be refrigerated, while others, such as controlled sub-
stances and narcotics, are required to be stored in secure areas, such as
a caged-in area of the facility or a vault). Once orders are received
3. See Prescription Drug Marketing Act of 1987, 21 U.S.C. § 353 (2005); 21 C.F.R. §
205 (2005).
4. For example, in states such as Ohio and Nevada, it is the state pharmacy board that
licenses, inspects, and disciplines wholesale distributors. However, in Louisiana, there exists
a state board of wholesalers who is tasked with this responsibility. Lastly, in other states such
as Texas and Florida, the state department of public health is the entity responsible for regu-
lating wholesalers.
4
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from health care providers such as pharmacies and hospitals, those
products are then picked and delivered to the appropriate location for
administration to patients. This, in essence, is how the system works
in the majority of cases.
However, in a few cases, there may be pharmaceutical wholesale
distributors that purchase pharmaceuticals for the exclusive purpose of
selling them to other wholesalers. These wholesalers are commonly
referred to as alternate source vendors (ASVs), or secondary market
distributors. In this case, a pharmaceutical wholesale distributor may
have purchased product from an ASV, as opposed to obtaining the
product directly from the manufacturer. In addition, some pharmaceu-
tical wholesale distributors that are not ASVs per se may also have
purchased product from each other depending upon the situation.
Lastly, there are situations where even pharmacies and health care
providers may purchase product and sell it between themselves. As
such, the concept that pharmaceutical products only come from the
manufacturer directly to one wholesaler, who in turn sells it to one
health care provider, who then dispenses or administers it to a patient,
does not occur in every situation. However, this is indeed the case a
vast majority of the time.
One question that may arise is why a pharmaceutical distributor
would purchase from an ASV or another distributor as opposed to
only purchasing product directly from the manufacturer. In addition
to pricing issues that motivate some purchases in the ASV market-
place, there are also situations where product shortages, backorders
and limitations occurring at the manufacturer result in product out-
ages. To be able to service health care provider demands, non-
manufacturer suppliers have been utilized. Unfortunately, it appears
that this has been one of the avenues by which counterfeit product has,
on rare occasions, entered the distribution system.
In light of the potential risk of counterfeit product being intro-
duced into the drug distribution system through the ASV marketplace,
the wholesale drug distribution industry, and in particular the Big
Three distributors, has taken steps to help protect against such occur-
rences. Through its trade association, the industry has established
standards in the HDMA Recommended Guidelines for Pharmaceutical
Distribution System Integrity,5 which establish how distribution activi-
5. See HEALTHCARE DISTRIBUTION MGMT. ASS'N, RECOMMENDED GUIDELINES FOR
PHARMACEUTICAL DISTRIBUTION SYSTEM INTEGRITY (2003), http://www.healthcare distribu-
tion.org/gov-affairs/anti.asp (follow "Recommended Guidelines for Pharmaceutical Distribu-
tion System Integrity" hyperlink).
20051
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ties should be conducted to substantially reduce any threat of counter-
feit products. In addition, some distributors such as Cardinal Health,
have established internal requirements and procedures that exceed
regulatory or industry guidelines to help further ensure the integrity of
products received into their distribution systems. In Cardinal Health's
case, today over 99% of pharmaceuticals are purchased directly from
the manufacturer. Purchases from other distributors are only made
from fully licensed (federal and state) entities, and only after Cardinal
Health performs a rigorous assessment to validate that the systems
those vendors use are compliant and robust. This includes Cardinal
Health auditing those vendors and establishing that they meet its sup-
plier qualifications. In addition, today Cardinal Health will only
source brand name prescription pharmaceuticals directly from their
manufacturers. Cardinal Health also continually evaluates which new
and existing products may pose a potential counterfeiting risk and ex-
cludes the purchase of such drugs from anyone other than the manu-
facturer. Also, all of Cardinal Health's non-manufacturer suppliers
are reviewed on a regular basis, and Cardinal Health discontinues do-
ing business with any supplier when a concern arises about the integ-
rity of the product being sold by that supplier or where the supplier
fails to comply with regulatory and industry guidelines.
Technology
As a result of concerns regarding the integrity of the supply chain,
the FDA and a number of state agencies and lawmakers have focused
upon what more can be done to help prevent counterfeit drugs from
entering the U.S. health care system. The FDA's February 18, 2004
report entitled Combating Counterfeit Drugs: A Report of the Food
and Drug Administration, and subsequent update on May 18, 2005,
discussed various technologies that may provide value in this regard.6
We will discuss two such technologies: 2D Serialized Bar Codes and
Radio Frequency Identification (RFID). Both technologies employ an
Electronic Product Code (EPC) that utilizes a unique identification
number that provides serialization for each individual item. In doing
so, the EPC number accompanies each legitimate item, thus allowing
those parties distributing the product to authenticate the product as it
6. FDA, COMBATING COUNTERFEIT DRUGS: A REPORT OF THE FOOD AND DRUG
ADMINISTRATION (2004), available at http://www.fda.gov/oc/initiatives/counter-
feit/report02_04.html; FDA, COMBATING COUNTERFEIT DRUGS: A REPORT OF THE FOOD AND
DRUG ADMINISTRATION ANNUAL UPDATE (2005), available at http://www.fda.gov
/oc/initiatives/counterfeit/update2005.htnl.
6
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moves through the supply chain. Ideally, EPC-based technology
should work to identify only a legitimate item and determine where it
has been.
2D Serialized Bar Codes
2D Serialized Bar Codes (2D Bar Codes) are similar to the typical
linear bar codes (e.g., ID bar codes) that many consumers see at the
checkout line. However, 2D Bar Codes provide much more informa-
tion. Unlike a typical linear bar code, 2D Bar Codes have the ability
to hold literally hundreds of characters in a very compressed area. In
addition, 2D Bar Codes can contain information specific for that par-
ticular drug product, such as a unique serial number per drug unit, a
manufacturer's lot number, expiration dating for the product, and the
FDA's National Drug Code (NDC) number. This 2D Bar Code "seri-
alization" process would have to begin with each manufacturer assign-
ing a 2D Bar Code and information to its product, and placing the bar
code on each commercial sale unit it distributes. From there, each bar
coded unit could then be physically scanned by each entity in the sup-
ply chain (e.g., the wholesale distributor, the pharmacy, or another
health care provider) to help verify the packages' authenticity. In or-
der to track and trace authentic product movements, the read informa-
tion would have to be stored in a database and updated on a continual
basis.
There are some significant challenges to the use of this technology
from the pharmaceutical wholesale distributor's perspective. First, it
is essential that manufacturers using the 2D Bar Code technology
adopt the same data standard. If different standards are employed, this
will adversely impact the ability of distributors (and health care pro-
viders such as pharmacies) to cost-effectively adopt this infrastructure.
Second, the process of physically scanning each and every item so as
to input that information into a supply chain database will increase
costs and slow down efficiencies. Distribution centers receive cases
of product from manufacturers. To be able to record what product
was received, each item would have to be removed from its case at the
warehouse, physically scanned, and then stored. Currently, manufac-
turers' cases are not opened until product is needed for deliveries. In
addition, many large wholesale distribution operations have automated
pickers that are used to retrieve product within the warehouse, which
is then placed into delivery totes. An example of such technology is a
machine called the A-Frame. A typical A-Frame holds about 50,000
items and on average picks about 8300 items per hour. This amounts
2005]
7
Giacalone,: Drug Wholesaling and Importation: Challenges and Opportunities
Published by CWSL Scholarly Commons, 2005
72 CALIFORNIA WESTERN INTERNATIONAL LAW JOURNAL [Vol. 36
to approximately 138 items being picked every minute. The A-Frame
is not situated to be able to scan 2D Bar Code labels. Hence, human
intervention would be needed to scan each unit slated for delivery.
Thus, the efficiencies associated with this technology would be ad-
versely impacted. Lastly, there is uncertainty over who would de-
velop and maintain a single database to store the millions of records of
all pharmaceuticals manufactured and distributed in the United States.
This would be a significant undertaking and critical to the success of
an industry-wide technology initiative.
Radio Frequency Identification
RFID is another form of track and trace technology that has re-
ceived significant public attention. RFID generally consists of elec-
tronic tags (comprised of an electronic circuit and an integrated an-
tenna) that allow for electromagnetic waves to be identified by
readers. These readers capture the signals received from these elec-
tronic tags and interpret the data stored on the tag's chip. This data
could include a unique identifier per drug unit, a NDC number, or
other information. The benefit that RFID ideally has over other tech-
nologies such as 2D Bar Codes is that RFID does not require line-of-
sight scanning since radio waves are transmitting information to elec-
tronic readers. Thus, ideally RFID, if implemented as intended,
should help to address the efficiency issue mentioned earlier. While
RFID holds much promise, the application of this technology cur-
rently has significant limitations.
A pilot study was commenced in October 2003 as a proof of con-
cept to determine whether RFID technology could effectively be used
within the pharmaceutical supply chain system. Cardinal Health par-
ticipated with a dozen companies comprised of manufacturers, other
wholesale distributors, and retail pharmacies in an RFID pilot program
referred to as Project Jumpstart.7 The pilot program involved the
manual tagging of certain drug items at the manufacturer level with
readers provided at the pharmaceutical wholesale distributor and
pharmacy level to read and record the information provided by the
7. Companies involved in the Project Jumpstart pilot program included manufacturers
such as Abbott Laboratories, Barr Laboratories, Merck & Co., Johnson & Johnson, Novartis,
Procter & Gamble, Pfizer, Sanofi-Synthelabo, and Wyeth; pharmaceutical wholesale distribu-
tors such as Cardinal Health and McKesson; and retail pharmacies such as CVS, Rite-Aid and
Walgreens. In addition, Accenture served as the program manager for the group and industry
trade associations. The Healthcare Distribution Management Association (HDMA) and the
National Association of Chain Drug Stores (NACDS) were also part of the working group.
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electronic tags. The results of the pilot, while promising, were not a
resounding endorsement for using this technology in its current state.
Some of the data provided from the pilot found that of the 20,564
RFID tags received for use, only 73% of those tags were readable
prior to their application to the pharmaceutical containers by the
manufacturer. In addition, of those RFID tags that were readable at
the manufacturer level, the failed reads for wholesaler distributors of
those same tags at the distributors' warehouses were between 3.5%
and 21%. In addition, it took between three and fifteen minutes to
read a full case containing RFID labeled drugs, due to radio wave in-
terference which, at times, was caused by the RFID tags themselves.
As such, while RFID technology holds promise for the future in
terms of deterring counterfeiting, improving supply chain efficiencies
(e.g., inventory management, tracking returns, and outdated product),
assisting in recall identification and process, and ideally enhancing pa-
tient safety (e.g., bedside administration), the technology currently has
significant limitations. RFID (and to some extent 2D Bar Codes) pro-
vide added costs and expenses in terms of tags or bar codes and read-
ers or scanners. Also, such technology requires additional labor and
time in the distribution process due to their current incompatibility
with existing systems. Furthermore, the issue regarding ownership of
the supply chain database, as in the case of 2D Bar Code technology,
still exists. In addition, RFID technology has been shown to be ad-
versely affected by other existing technology (e.g., wireless tele-
phones), and there exists a lack of standards currently in place for
REID that also poses a problem in determining which RFID system(s)
to utilize. Lastly, there remains a significant question as to whether all
participants will choose to take part in the process and which technol-
ogy they will adopt. Without the participation of each and every
stakeholder (e.g., manufacturers, wholesale distributors, pharmacies,
and other affected health care providers), the system will not operate
efficiently or effectively. Partial implementation of RFID or other
technology adds significant costs and expenses without establishing
the safeguards needed to ensure product integrity and traceability
throughout the continuum of the supply chain.
Potential Implications of Importation into the United States
Supply Chain Integrity
Recently, there has been much discussion of drug importation and
the potential economic benefit to U.S. citizens in being able to pur-
chase affordable pharmaceuticals. While numerous consumer groups
2005]
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and some legislators support such efforts, the legality of doing so un-
der existing law is questionable. First, the American Goods Returned
provisions of the Federal Food, Drug, and Cosmetic Act essentially
state that no prescription drug that "is manufactured in a State and ex-
ported may be imported into the United States unless the drug is im-
ported by the manufacturer of the drug."8 Furthermore, violations of
this statute carry potential criminal penalties of up to ten years in
prison and/or $250,000 in fines. In addition, while Congress passed
legislation to allow pharmacists and wholesalers to import prescription
pharmaceuticals into the United States, this could only be done pro-
vided the Secretary of the U.S. Department of Health and Human Ser-
vices found that sufficient safeguards were in place to ensure that such
imported product is safe and effective for its intended use and is in ac-
cord with other requirements set forth under the Food, Drug, and
Cosmetic Act. Furthermore, the Secretary was to certify to Congress
that the implementation of this section will "pose no additional risk to
the public's health and safety" and will "result in a significant reduc-
tion in the cost of covered products to the American consumer."9 To
date, the Secretary has yet to provide this certification.
In addition, the Food, Drug, and Cosmetic Act only permits prod-
ucts approved by the FDA to be marketed and sold within the United
States. Hence, products not having an approved New Drug Applica-
tion (NDA) or Abbreviated New Drug Application (ANDA) with the
FDA or falling under some other limited exception (e.g., pre-1938 or
pre-1962 grandfathered products) cannot legally be sold within the
United States. Furthermore, the FDA has established manufacturing,
packaging, and labeling requirements which may not be met by a sig-
nificant number of foreign produced pharmaceutical products. Hence,
those products also cannot be sold in the United States under existing
federal requirements.'° In addition, the FDA has been fairly adamant
in its position that drug reimportation is illegal and that it will prose-
cute those choosing to undertake such activities. Various states have
also taken action against pharmacies that have either directly or indi-
rectly tried to have product dispensed to U.S. citizens from pharma-
cies located outside of the United States."
8. 21 U.S.C. § 381(d)(1) (2005).
9. 21 U.S.C. § 384(1) (2005).
10. See U.S. DEP'T OF HEALTH & HUMAN SERVS., HHS TASK FORCE ON DRUG
IMPORTATION: REPORT ON PRESCRIPTION DRUG IMPORTATION (2004), available at
http://www.hhs.gov/importtaskforce/Report1220.pdf [hereinafter HHS TASK FORCE].
11. One example of such state activity was where the Alabama State Board of Phar-
macy obtained injunctive relief against Discount Drugs of Canada prohibiting them from dis-
10
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Aside from the significant legal hurdles that currently exist with
drug importation by pharmaceutical wholesale distributors (and other
non-manufacturing entities), supply chain concerns also exist. Cur-
rently, the U.S. drug distribution system is essentially a "closed" sys-
tem, wherein product moves between certain select entities (e.g.,
manufacturers, wholesale distributors, and pharmacies) until it ulti-
mately reaches the patient. All of these health care entities fall under
the jurisdiction and authority of federal and/or state regulatory bodies.
Thus, licensure requirements, inspection activities, and enforcement
activities can and do occur, wherein the regulated entities all follow
essentially the same standards and requirements depending upon their
industry. In contrast, foreign entities many times do not follow U.S.
requirements and standards. In addition, it has been found that a
number of foreign governments have little incentive to ensure that
drugs exported from their respective countries are safe and effective.
Thus, reliance upon the regulatory process, paper validation, and li-
censing practices conducted by foreign regulatory bodies, where
product is destined for export to U.S. citizens, may be misplaced. 12 As
a result, what was once a "closed" system is again "opened" by the
addition of foreign suppliers such as foreign wholesale distributors or
pharmacies.
Some commentators have asserted that technology such as RFID
and bar coding can be employed to ensure that product entering the
United States is not counterfeit and can validate that such product
meets those requirements set forth under the Federal Food, Drug, and
Cosmetic Act. As mentioned earlier in this essay, practical challenges
currently exist for the effective implementation of technologies such
pensing prescription medications to residents of Alabama. See Alabama State Bd. of Phar-
macy v. Discount Drugs of Canada, No. CV 03-1742 (Ala. Cir. Ct. Jefferson County Mar. 31,
2003) (order granting preliminary injunction). In addition, the FDA was also successful in
obtaining injunctive relief against another pharmacy, Rx Depot, wherein Rx Depot, Inc. and
Rx of Canada, LLC assisted U.S. residents in having prescriptions filled outside of the United
States by Canadian pharmacies. See United States v. Rx Depot, Inc., 290 F. Supp. 2d 1238
(N.D. Okla. 2003) (order granting preliminary injunction).
12. See HHS TASK FORCE, supra note 10, at xi, 62. For example, in Canada, the Health
Products and Food Branch (HPFB) of Health Canada regulates drugs by the review of appli-
cations for marketing authorizations and Drug Establishment licenses. However, under sec-
tion 37(1) of the Canadian Food and Drugs Act, an entity can be exempted from the require-
ments of obtaining a Drug Establishment license and complying with Canadian Good
Manufacturing Practices (GMP) if the drug is intended for export from Canada and so identi-
fied. Thus, "[i]f a Canadian fabricator chooses to invoke Section 37 for a drug, the Inspector-
ate will not verify GMP compliance for the process related to that specific drug, and therefore
the Inspectorate cannot attest to the quality of the fabricator's products." See HEALTH PRODS.
& FOOD BRANCH, HEALTH CAN., GUIDANCE DOCUMENT ON THE COMMERCIAL IMPORTATION
AND EXPORTATION OF DRUGS IN DOSAGE FORM UNDER THE FOOD AND DRUGS ACT (2003).
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as RFID. In addition, standards for technology like RFID have yet to
be uniformly established in the United States, as well as the rest of the
world. For example, differences exist as to what radio frequency is
permitted in Europe versus the United States. Also, countries with
limited supplies of pharmaceuticals (such as Canada) are taking steps
to limit exports, in an effort to guard against product shortages that
might result from the flow of their lower-priced drugs to the United
States. Manufacturers may also be economically disincentivized to
tag and readily identify foreign product suitable for sale and importa-
tion into the United States. Price control mandates in foreign coun-
tries limit what manufacturers can charge for such products abroad.
To have those foreign products readily identifiable and capable of be-
ing shipped into a more lucrative market such as the United States
would adversely affect that manufacturer's U.S. sales.
CONCLUSION
The pharmaceutical wholesale distribution industry has taken sig-
nificant strides to establish a secure distribution system where patient
safety is the leading goal. Ongoing assurance programs, audits of
suppliers, increased regulatory requirements, and work with emerging
technologies have all been instrumental in helping to prevent counter-
feit drugs from entering the U.S. pharmaceutical supply chain. If a
decision to move forward with importation is made, pharmaceutical
wholesaler distributors, with systems and infrastructures in place to
protect product integrity and detect and deter counterfeit drugs, would
be best equipped to maintain the safety and security of the national
drug supply. Nonetheless, there are significant challenges that must
first be addressed to ensure the broad safety of imported products
while maintaining the desired cost benefits for consumers. The two
key areas that any approach to importation must address are product
authentication and ensuring the integrity of imported products for the
U.S. market. However, until more reliable means are established, sig-
nificant concerns remain as to the safety of importing or reimporting
prescription pharmaceuticals from foreign non-manufacturing sources.
12
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